HONG KONG, SAR, Aug. 22, 2022 /EINPresswire.com/ — Forest Hills Lab (FHL) is an innovative regenerative medicine company that seeks to improve the quality of life in our rapidly aging society. FHL’s Neuro-Med division, which is a therapeutic drug development platform focused on neurodegenerative diseases, today announces the expansion of its pipeline and the update of its clinical development programs.
The FHL pipeline has grown from two to eight candidates. This expansion reflects the fact that neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease are heterogeneous and will likely require multiple approaches for effective treatment. The expanded pipeline also supports FHL’s platform business model to enable the company to rapidly develop its candidates and form strategic alliances with multiple partners to accelerate pipeline development. Candidates in the pipeline today encompass a variety of disease-modifying mechanisms of action, as well as novel and refocused drugs. Besides oral administration, several candidates have also shown promising preclinical data when administered intranasally, which may allow for more efficient delivery across the blood-brain barrier.
Several candidates in FHL’s pipeline have been licensed from Dr. Kalipada Pahan’s lab at Rush University. Pahan, who also sits on FHL’s Scientific Advisory Board, said, “We are excited to continue our partnership with Forest Hills Lab to bring discoveries from our lab to patients with neurodegenerative diseases in need. These candidates have shown effects including reduced levels of alpha-synuclein and amyloid beta in animal models of Parkinson’s and Alzheimer’s disease, respectively. We expect these effects to translate well into clinical development. »
Additionally, FHL is preparing for the clinical development of several of its pipeline programs. FHL-301 is a refocused drug gearing up to move into phase II trials for patients with Parkinson’s disease. FHL-101 is a new chemical entity that has recently received Investigational New Drug approval to proceed to Phase I trial, while FHL-201 is also close to being ready to start trials. phase I studies.
“We are proud that FHL has made excellent progress in the clinical development of our lead drug candidate shortly after another drug candidate was cleared to begin Phase 2 trial last year. Parkinson’s and Alzheimer’s diseases represent an extraordinary burden for patients and society in general. We hope that FHL therapies can become effective, patient-friendly, disease-modifying treatments in the near future,” said Alex Yang, Chairman and CEO of Forest Hills Lab.
About Forest Hills Lab
Forest Hills Lab is an innovative regenerative medicine company that seeks to improve the quality of life in our rapidly aging society. FHL is made up of two divisions: Neuro-Med and Cos-Med. FHL’s Neuro-Med division is a therapeutic drug development platform focused on high unmet need neurodegenerative diseases. The Cos-Med division of FHL develops and markets a full line of aesthetic products worldwide.
Forest Hills Lab’s largest shareholder is Mstone Partners, an entrepreneurial biotechnology incubator in the form of a holding company that owns and manages a portfolio of drug development companies. Mstone focuses on pediatric and repurposed drugs, rare and neurodegenerative diseases and innovative technologies for targeted indications. Since its inception in 2016, Mstone has invested in two US companies and one in Hong Kong, which are now in advanced clinical stages with the US FDA. Mstone has also created a number of portfolio companies under the Curestone platform, which manages a portfolio of drug development companies in a centralized hub-and-spoke model.
For more information, please visit https://foresthillslab.com/.
Forest Hills Laboratory